Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy.

Authors

Florian Van Oers, Zoi Katana, Donovan Flumens, Eva Lion, Diana Campillo-Davo

Published in

Molecular therapy. Nucleic acids. Volume 37. Issue 3. Pages 102994. Sep 08, 2026. Epub Jun 24, 2026.

Abstract

Electroporation of messenger RNA (mRNA) is an ex vivo non-integrating gene transfer technique used in immune-cell-based trials for cancer to transiently supply immune cells with multiple proteins. This technique has been used to engineer dendritic cells and B cells with tumor-associated antigens to boost the immune system of cancer patients and to redirect the anti-tumor activity of T cells and natural killer cells with immune receptors. Although gene delivery via mRNA electroporation results only in transient expression of the protein of interest, many investigators and clinicians consider it as a feasible, flexible, and safe technique, compared with stable expression methods using viral vectors. In this review, we discuss the efficacy of mRNA electroporation for gene transfer and assess the strengths and limitations of this technique for redirecting and boosting immune responses against various tumor antigens in cancer immunotherapy.

PMID:
42437306
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.